Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007097 (carcinoma)
 152,788 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We may recapitulate: Chemotherapy, first of all with adriamycin, has proved successful in thyroid cancer even after exhaustion of the therapeutic measures used so far. The combination of adriamycin with bleomycin and Velbe, corresponding to our preliminary experiences, seems to be superior to a monotherapy with adriamycin. The side effects remain absolutely tolerable. Hence follows concerning further procedure that chemotherapy has to be applied earlier than practiced up to now, i.e. as soon as criteria for metastasition are observed and/or if the primary treatment--operation and irradiation--does not satisfy. Cytostatic therapy apparently is the optimal treatment technique in medullar carcinoma. But it is necessary, moreover, to search for other effective combinations of chemotherapeutic agents, especially in the case of anaplastic carcinoma. Chemotherapy, assisted by thyroid hormone treatment, can certainly be improved further by a more severe assessment of the indication, by early application and, last not least, by better coordination with surgical and radiotherapeutical action.
 ...
PMID:[Drug therapy of thyroid malignomas (author's transl)]. 7 50

Human hematopoietic cells can be maintained in vitro for many weeks in the absence of exogenously provided hematopoietic growth factors if an adequate stromal cell containing adherent layer is present. We have now extended the use of this type of long-term culture (LTC) system to create a model of perturbed hematopoiesis in which human tumor cells that constitutively produce a variety of factors are co-cultured together with normal human marrow cells. In the present study, we used the human bladder carcinoma cell line (5637) because these cells were known to produce not only a variety of factors active directly on hematopoietic cells but also factors that can stimulate hematopoietic growth factor production by human marrow stromal cells. Analysis of mRNA extracted from the adherent layer and measurement of growth factor bioactivity in the medium of established LTC of human marrow containing irradiated 5637 cells, showed increased levels of interleukin-1 and -6, as well as granulocyte and granulocyte-macrophage colony-stimulating factor production by comparison to control cultures. As in normal cultures, high proliferative potential clonogenic hematopoietic cells were found almost exclusively in the adherent layer of these co-cultures, but these primitive cells were maintained in a state of continuous turnover, in contrast to control cultures where the same cell types showed the expected oscillation between a quiescent and a proliferating state following each weekly change of the medium. A similar perturbation of primitive progenitor cycling was achieved by adding medium conditioned by 5637 cells twice a week to otherwise normal LTC. The presence of irradiated 5637 cells in the LTC or the addition of 5637 conditioned medium also resulted in modest (2- to 3-fold) but sustained increases in the total hematopoietic progenitor population, as well as in the final output of terminally differentiated granulocytes and macrophages. These findings indicate that primitive hematopoietic cells in LTC can be kept in a state of continuous activation for many weeks by appropriate endogenous or exogenous hematopoietic growth factor provision and that this does not necessarily lead either to their rapid exhaustion or to a large amplification in output of mature progeny.
 ...
PMID:Continuous activation of primitive hematopoietic cells in long-term human marrow cultures containing irradiated tumor cells. 171 96

Hypercoagulability develops after surgery for esophageal carcinoma, and it related closely to postoperative complications. This study evaluated the effects of the synthetic proteinase inhibitor, Cabexate Mesilate (FOY), on this hypercoagulability. The subjects used were 25 patients with a mean age of 63 who had undergone surgery for esophageal carcinoma. Of these, eight patients (test group) received FOY (2,000 mg/day) for three to 23 days after surgery, but 17 (control group) did not. In the test group, FOY controlled aggregation and release of the platelets and minimized their exhaustion. FOY almost completely checked the abnormal increase in thrombin activity which might trigger the hypercoagulability. Also, FOY suppressed the fibrinolytic activity slightly. These results indicate that FOY is effective in controlling hypercoagulability after surgery for esophageal carcinoma and in suppressing activity of the proteinases that cause both blood coagulation and fibrinolysis.
 ...
PMID:[Effects of the synthetic proteinase inhibitor, FOY, on hypercoagulability after surgery for esophageal carcinoma]. 212 27

A new depot formulation of the LHRH analogue Zoladex (goserelin acetate) has been developed which releases the drug over a period of at least 3 months as judged by measurement of drug content in depots at intervals after insertion in male rats and by the suppression of oestrogen secretion and oestrus in female rats. This formulation is based on the lactide/glycolide polymer system used for the standard 1-month Zoladex depot, but the dose has been increased to 10.8 mg and the characteristics have been modified to enable a longer release of drug to be achieved. Thirty-eight patients with histologically proven, locally advanced (stage T3 or T4) and/or metastatic prostate cancer were treated with this new longer acting LHRH analogue depot formulation containing 10.8 mg Zoladex. After initial increase of serum testosterone in the first week of therapy, castration levels were reached in all patients after 4 weeks and this was maintained for more than 14 weeks. At the time of depot exhaustion, when escape from castration levels of androgen occurred, all patients received a single injection of a standard 1-month depot containing 3.6 mg Zoladex which restored castration levels of androgen thus showing that the pituitary gland was again suppressed. The tolerance and acceptability of the longer-acting depot is high and comparable to the 1-month depot. Taking into account social and psychological factors, patients with advanced prostate carcinoma will soon be able to be treated with a longer acting LHRH depot formulation every 3 months an alternative of the 1-month depot now widely used clinically.
 ...
PMID:A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer. 214 7

Preparation of highly active rabbit antisera (AS) to human recombinant alpha 2-interferon and their use for studying biological properties of natural and plasmid alpha-interferons are described. By exhaustion of AS by alpha 3-interferon there were prepared practically monospecific AS not reacting with antigenic determinants of alpha 3-interferon. It was found that alpha 3-interferon represented a significant portion of human lymphoblastoid interferons and was included in PH-labile alpha-interferon from serum of patients with Kaposi carcinoma. AS to alpha 2-interferon completely neutralized antiviral and antiproliferative activity of the homologous subtype alpha-interferon and stimulation of cytotoxicity of human natural killer cells induced by it. It neutralized also the same effects of the heterologous subtypes (alpha 3 and alpha F/D) and leukocytic interferon, but the neutralization level was lower. The results of the study confirmed the polyfunctional nature of the interferon molecule.
 ...
PMID:[Biological activity of human alpha-interferons studied using specific antisera]. 246 45

Functions of adrenal gland cortex, mediator system of brain and of sympathoadrenal system, including hormone formation in medullar layer of adrenal glands, were studied in mice of C57BL strain with growing metastatic Lewis carcinoma. The neurohormonal activity was distinctly inhibited under conditions of stress within the period of adaptation to the tumor development (I-14 days after the carcinoma inoculation) as well as in development of metastases (21 day of the tumor growth). Excessive stimulation of the systems studied as well as their exhaustion, might cause a distinct augmenting effect on the tumor growth and development of metastases.
 ...
PMID:[Neurohormonal changes during the growth of metastatic Lewis carcinoma in C57Bl mice]. 286 42

The phase changes of biochemical characteristics of hypothalamic mediator systems have been demonstrated in C57Bl mice with Lewis carcinoma. Phase I generated due to implantation of tumour cells was characterized by predominant exciting processes, which can increase the dissemination and sedimentation of tumour cells. During phases II--a period of metastatic formation--the normalization was found in hypothalamic mediator systems, which along with the activation of serotoninergic mechanisms promotes the inhibition of antitumour resistance. Phase III was related to the acute activation of mediator exciting processes and weakening of inhibition processes. Stress reactions arising under these conditions can stimulate tumour cell extravasation and development, and active growth of early metastatic nodules. The depletion of exciting mediator systems of the hypothalamus followed by general exhaustion of the organism was observed in phase IV.
 ...
PMID:[Mediator processes in the hypothalamus in the development of Lewis pulmonary carcinoma]. 286 80

On the basis of 8 patients of our own and a survey of the literature, the present state of chemotherapy of thyroid carcinoma is discussed. Chemotherapy is only indicated in cases of progressing disease after exhaustion of all conventional therapies. Only in cases of undifferentiated giant- or spindle-cell thyroid carcinomas can chemotherapy following conventional treatment be approved right from the beginning. The three most widely applied cytostatics are adriamycin, bleomycin and cis-platinum, and it seems that adriamycin monotherapy, is superior to all other therapies, even combinations, except probably for the undifferentiated thyroid carcinoma. In addition to the patient's general condition, a sufficiently high single dose of adriamycin, which should be increased in case of nonresponse, appears to be essential for the therapeutical effect. Due to its low toxicity, especially cardiotoxicity, 4'-epi-adriamycin, which, while being almost as effective, can be applied at higher doses and over longer periods, seems to be promising. Approximately 1/3 of thyroid carcinomas respond to adriamycin monotherapy, the response rate probably being highest for medullary types and lowest for undifferentiated thyroid carcinomas. The highest response is observed in the case of pulmonary metastases, followed by bone metastases and local tumor growth. If thyroid carcinomas respond to chemotherapy--even by no-change behavior only--a prolongation of median survival rates from 3-5 months (nonresponders) to 15-20 months (responders) can be achieved.
 ...
PMID:Chemotherapy of thyroid carcinoma. 362 2

Seventy malignant lymphomas of the gastro-intestinal tract (GIT) (54 lymphosarcomas, 16 lymphogranulomatoses) were studied. GIT lymphosarcomas and lymphogranulomatosis are characterized by the similarity of histogenesis, morphogenesis, and forms of progression. The lymphoid apparatus of GIT is the source of tumor growth, the tumor develops multicentrically and not simultaneously, the progression occurs as autochthonous growth, metastasizing. Isolated GIT lymphomas have a potential trend for generalization. In lymphosarcomas, the predominant histological types are prolymphocytic and lymphoblastic, in lymphogranulomatosis--mixed-cell and lymphocyte exhaustion. Differential diagnosis must distinguish between malignant lymphoma and pseudolymphoma, different variants of lymphomas and low-differentiated carcinoma, which requires examination of the operation material, knowledge of the typical cytological and histological features of lymphoma variants, and the use of the required complex of histological and histochemical methods.
 ...
PMID:[Malignant lymphomas of the gastrointestinal tract (problems of histogenesis, morphogenesis and histological diagnosis)]. 712 27

Thirty patients with histologically proven metastatic mammary carcinoma were treated, after exhaustion of hormonal and cytostatic therapeutic means, with high-dosed medroxyprogesterone acetate (MPA) during a ten-day induction phase with 1000 mg MPAi.m. per day and then with 600 mg oral MPA per day. In eleven patients a complete or partial remission was achieved. The median period of remission comprised ten months. A positive relationship was found between the response to high-dosed MPA therapy and the length of free intervals. Side effects were tolerable.
 ...
PMID:[High-dosed gestagen therapy of the metastatic mammary carcinoma (author's transl)]. 733 Sep 9


1 2 3 4 Next >>